Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidance Webinar Series

Guidance Webinar Series Home
          Training and Continuing Education
          Guidance Webinar Series
          FDA Webinar: Draft Guidance For Industry On Alzheimer’s Disease: Developing Drugs For The Treatment Of Early Stage Disease; Availability - March 28, 2013Guidance Webinar Series FDA Webinar: Draft Guidance For Industry On Alzheimer’s Disease: Developing Drugs For The Treatment Of Early Stage Disease; Availability - March 28, 2013
  
  	
    Share
    Post
    Linkedin

    Email
    PrintOn March 28, 2013, FDA presented a webinar on a new draft guidance entitled "Draft Guidance For Industry On Alzheimer’s Disease: Developing Drugs For The Treatment Of Early Stage Disease; Availability."

The webinar provided an opportunity to learn about the guidance from individuals involved in its preparation. It is also intended to encourage the submission of questions or comments while the guidance is still in draft form.

Questions were submitted online during the webinar and were addressed as time permitted. All questions should also be submitted to docket so that they can be formally processed by FDA.



View Presentation Here: https://collaboration.fda.gov/p73232265

Download Presentation Slides: Developing Drugs For The Treatment Of Early Stage Disease (PDF – 481KB)



FR NOTICE

http://www.gpo.gov/fdsys/pkg/FR-2013-02-08/pdf/2013-02863.pdf



Date Published: 02/08/2013

Deadline for Comments: 04/09/2013



**Contact**: Nicholas A. Kozauer

Center for Drug Evaluation and Research

Food and Drug Administration

10903 New Hampshire Ave.

Bldg. 22, Rm. 4351

Silver Spring, MD 20993–0002

301–796–2250



SPEAKER:

Russell G. Katz, MD

Director, Division of Neurology Products

CDER/FDA

(301) 796-2250



Archive of Past Webinars:

http://www.fda.gov/Training/GuidanceWebinars/default.htm



If you have never attended a Connect Pro meeting before, please test your connection before the lecture by following this link: https://collaboration.fda.gov/common/help/en/support/meeting_test.htm



ResourcesForYou

                                                                                  Content current as of:
      05/04/2016Guidance Webinar Series
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop